0711 TASIMELTEON ENTRAINS THE CIRCADIAN CLOCK IN TOTALLY BLIND INDIVIDUALS WITH NON-24 HOUR SLEEP-WAKE DISORDER (NON-24) IMPROVING SLEEP-WAKE MEASURES
نویسندگان
چکیده
منابع مشابه
Non-24-Hour Sleep–Wake Rhythm Disorder in the Totally Blind: Diagnosis and Management
Several aspects of human physiology and behavior are dominated by 24-h circadian rhythms with key impacts on health and well-being. These include mainly the sleep-wake cycle, vigilance and performance patterns, and some hormone secretions. The rhythms are generated spontaneously by an internal "pacemaker," the suprachiasmatic nuclei within the anterior hypothalamus. This master clock has, for m...
متن کاملNon-24-Hour Sleep-Wake Disorder Revisited – A Case Study
The human sleep-wake cycle is governed by two major factors: a homeostatic hourglass process (process S), which rises linearly during the day, and a circadian process C, which determines the timing of sleep in a ~24-h rhythm in accordance to the external light-dark (LD) cycle. While both individual processes are fairly well characterized, the exact nature of their interaction remains unclear. T...
متن کاملMechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
ISSUE Many individuals with total blindness can develop a circadian rhythm disorder-called non-24 sleep wake syndrome-because they cannot detect light to resynchronize their sleep-wake cycles. A new melatonin 1 and melatonin 2 agonist tasimelteon improves sleep in these patients, resetting their circadian sleep-wake clocks.
متن کاملHETLIOZ is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). 2 DOSAGE AND ADMINISTRATION
_______________ WARNINGS AND PRECAUTIONS_______________ May cause somnolence: After taking HETLIOZ, patients should limit their activity to preparing for going to bed, because HETLIOZ can impair the performance of activities requiring complete mental alertness (5.1) ___________________ ADVERSE REACTIONS ___________________ The most common adverse reactions (incidence >5% and at least twice as h...
متن کاملNEW DRUG APPROVALS Hetlioz for Non-24-Hour Sleep-Wake Disorder
NEW DRUG APPROVALS Hetlioz for Non-24-Hour Sleep-Wake Disorder The FDA has approved tasimelteon (Hetlioz, Vanda Pharmaceuticals) 20-mg capsules for the treatment of non-24-hour sleep-wake disorder. Tasimelteon is the first FDA-approved medication for this chronic, circadian rhythm disorder, which results from a misalignment of the endogenous master body clock to the 24-hour day that disrupts th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Sleep
سال: 2017
ISSN: 0161-8105,1550-9109
DOI: 10.1093/sleepj/zsx050.710